The Effect of Dabigatran on Select Specialty Coagulation Assays

Dabigatran etexilate is a new oral anticoagulant that functions as a direct thrombin inhibitor. An inhibitor of thrombin has the potential to interfere with essentially all clot-based coagulation assays and select chromogenic assays, whereas the drug would not be expected to interfere in antigen-bas...

Full description

Saved in:
Bibliographic Details
Published in:American journal of clinical pathology Vol. 139; no. 1; pp. 102 - 109
Main Authors: Adcock, Dorothy M., Gosselin, Robert, Kitchen, Steve, Dwyre, Denis M.
Format: Journal Article
Language:English
Published: England Oxford University Press 01.01.2013
Subjects:
Activated Protein C Resistance - blood
Administration, Oral
Antithrombins - pharmacology
Benzimidazoles - pharmacology
Blood Coagulation - drug effects
Blood Coagulation Tests
Dabigatran
Diagnostic Errors
Factor VIII - analysis
False Positive Reactions
Humans
In Vitro Techniques
Partial Thromboplastin Time - methods
Protein S Deficiency - blood
Prothrombin - analysis
Pyridines - pharmacology
Thrombin - antagonists & inhibitors
ISSN:0002-9173, 1943-7722, 1943-7722
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dabigatran etexilate is a new oral anticoagulant that functions as a direct thrombin inhibitor. An inhibitor of thrombin has the potential to interfere with essentially all clot-based coagulation assays and select chromogenic assays, whereas the drug would not be expected to interfere in antigen-based assays. The purpose of this study was to evaluate the effect of dabigatran on various specialized coagulation assays using normal plasma specimens with varying concentrations of dabigatran (the active form of dabigatran etexilate). We have demonstrated that samples containing therapeutic levels of dabigatran may lead to underestimation of intrinsic factor activities with abnormal activated partial thromboplastin time (aPTT) mixing study results and a false-positive factor VIII Bethesda titer; overestimation of protein C and protein S activity and activated protein C resistance ratio when determined using aPTT-based methods; and overestimation of results based on chromogenic anti-IIa assays but no effect on antigen assays and select chromogenic assays.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-General Information-1
content type line 14
ObjectType-Feature-3
ObjectType-News-4
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:0002-9173
1943-7722
1943-7722
DOI:10.1309/AJCPY6G6ZITVKPVH